The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Lea MadiPnina Fishman

Abstract

A(3) adenosine receptor (A(3)AR) activation was shown to inhibit the growth of various tumor cells via the down-regulation of nuclear factor kappaB and cyclin D1. To additionally elucidate whether A(3)AR is a specific target, a survey of its expression in tumor versus adjacent normal cells was conducted. A(3)AR mRNA expression in various tumor tissues was tested in paraffin-embedded slides using reverse transcription-PCR analysis. A comparison with A(3)AR expression in the relevant adjacent normal tissue or regional lymph node metastasis was performed. In addition, A(3)AR protein expression was studied in fresh tumors and was correlated with that of the adjacent normal tissue. Reverse transcription-PCR analysis of colon and breast carcinoma tissues showed higher A(3)AR expression in the tumor versus adjacent non-neoplastic tissue or normal tissue. Additional analysis revealed that the lymph node metastasis expressed even more A(3)AR mRNA than the primary tumor tissue. Protein analysis of A(3)AR expression in fresh tumors derived from colon (n = 40) or breast (n = 17) revealed that 61% and 78% had higher A(3)AR expression in the tumor versus normal adjacent tissue, respectively. The high A(3)AR expression level in the tumor tiss...Continue Reading

References

Jul 1, 1996·British Journal of Pharmacology·A K DixonT C Freeman
Jul 27, 2000·American Journal of Physiology. Cell Physiology·D A CarréM M Civan
Sep 1, 2000·American Journal of Physiology. Renal Physiology·R ChenR V Paul
Aug 28, 2001·British Journal of Pharmacology·S GessiP A Borea
Sep 26, 2001·Experimental Cell Research·P FishmanS Pathak
Jul 27, 2002·Circulation Research·Richard G BlackJohn A Auchampach
Feb 7, 2003·Current Topics in Medicinal Chemistry·Arvinder K DhallaLuiz Belardinelli

❮ Previous
Next ❯

Citations

Apr 7, 2009·Purinergic Signalling·Nicholas WhiteGeoffrey Burnstock
Jun 26, 2013·Purinergic Signalling·Geoffrey Burnstock, Francesco Di Virgilio
Mar 7, 2006·Nature Reviews. Drug Discovery·Kenneth A Jacobson, Zhan-Guo Gao
Oct 7, 2009·Proceedings of the National Academy of Sciences of the United States of America·J P C da CunhaS J de Souza
Sep 28, 2010·American Journal of Respiratory and Critical Care Medicine·Katia VaraniPier Andrea Borea
Jan 31, 2014·International Journal of Molecular Sciences·Sandeep ShethVickram Ramkumar
Apr 5, 2014·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Karem ShanabHelmut Spreitzer
Aug 7, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Hamideh AbediSima Hajiahmadi
Oct 15, 2008·International Reviews of Immunology·Christopher C Fraser
Mar 23, 2012·Expert Opinion on Therapeutic Patents·Stephanie Federico, Giampiero Spalluto
May 30, 2014·Expert Review of Clinical Immunology·Sylvia Muller-HaegeleTheresa L Whiteside
Apr 5, 2011·Expert Opinion on Investigational Drugs·Balázs KoscsóGyörgy Haskó
Oct 10, 2007·Expert Opinion on Investigational Drugs·Sara Bar-YehudaPnina Fishman
Sep 19, 2007·Expert Opinion on Emerging Drugs·Zhan-Guo Gao, Kenneth A Jacobson
Dec 2, 2015·Oncology Letters·Xuewen TianLianshi Feng
Dec 20, 2014·Proceedings of the National Academy of Sciences of the United States of America·Jessie S JeonRoger D Kamm
Mar 5, 2013·Archives of Biochemistry and Biophysics·Monika Sakowicz-BurkiewiczTadeusz Pawelczyk
Oct 29, 2011·Drug Discovery Today·Pnina FishmanKenneth A Jacobson
Feb 22, 2005·Neoplasia : an International Journal for Oncology Research·Sara Bar-YehudaPnina Fishman
May 8, 2010·Nuclear Medicine and Biology·Daniela HaeuslerMarkus Mitterhauser
Dec 1, 2009·Urologic Oncology·Matthias PortMichael Abend
Apr 22, 2008·Bioorganic & Medicinal Chemistry Letters·Artem MelmanKenneth A Jacobson
Dec 27, 2007·Nuclear Medicine and Biology·Wolfgang WadsakMarkus Mitterhauser
Nov 22, 2007·Pharmacology & Therapeutics·Stefania GessiPier Andrea Borea
Mar 27, 2007·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Michal HoferDenisa Streitová
Nov 28, 2006·European Journal of Pharmacology·Karl-Norbert KlotzGloria Cristalli
Mar 9, 2005·British Journal of Pharmacology·Mojtaba PanjehpourKarl-Norbert Klotz
Mar 10, 2007·Journal of Cellular Physiology·Stefania GessiPier Andrea Borea
Aug 2, 2007·Medicinal Research Reviews·Maykel Pérez GonzálezMarta Teijeira
Sep 4, 2008·Journal of Cellular Physiology·Cynthia St HilaireKatya Ravid
Apr 25, 2013·Chemistry : a European Journal·Priyankar PairaGiorgia Pastorin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.